BPC-157Research, Evidence & Safety Profile

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a naturally occurring protein found in human gastric juice. First identified and isolated by researchers at the University of Zagreb in the 1990s, it has since become one of the most researched peptides in the healing and recovery space, often discussed alongside TB-500 — see our BPC-157 vs TB-500 comparison for the side-by-side mechanism breakdown.

Unlike many synthetic peptides, BPC-157 appears to be stable in human gastric juice, which has made it a subject of interest for both oral and injectable administration routes. The majority of research has been conducted in rodent models, where BPC-157 has demonstrated consistent healing effects across diverse tissues including muscle, tendon, ligament, bone, nerve, and gastrointestinal tissue.

It is important to note that as of 2026, BPC-157 has not received approval from the U.S. Food and Drug Administration (FDA) for any medical use. Its use in humans is largely experimental, and most knowledge about its effects in people is extrapolated from animal studies or anecdotal reports. Individuals considering BPC-157 should consult with a qualified healthcare provider.

BPC-157 exerts its effects through several interconnected molecular pathways:

• Angiogenesis promotion: BPC-157 upregulates vascular endothelial growth factor (VEGF) and its receptors, stimulating the formation of new blood vessels. Improved vascularization accelerates nutrient and oxygen delivery to damaged tissue.
• Nitric oxide modulation: The peptide interacts with the nitric oxide (NO) system, modulating both eNOS and nNOS activity. This influences vasodilation, blood flow, and cellular signaling relevant to healing.
• Growth factor upregulation: BPC-157 has been shown to increase expression of growth hormone receptors on tendon fibroblasts, amplifying the anabolic signaling cascade that drives collagen synthesis and tissue remodeling.
• Tendon-to-bone healing: It activates the FAK-paxillin pathway, which is critical for cell migration and attachment during tendon and ligament repair.
• Gut barrier protection: BPC-157 modulates the expression of tight junction proteins (claudin, occludin) in the intestinal epithelium, helping to maintain and restore gut barrier integrity.
• Neurotrophic effects: The peptide influences dopaminergic and serotonergic systems and has demonstrated neuroprotective properties in animal models of traumatic brain injury and peripheral nerve damage.

These multi-pathway effects help explain why BPC-157 appears to exert beneficial effects across such a wide range of tissue types.

The following potential benefits are supported primarily by preclinical (animal) research. Human clinical trial data remains limited.

• Accelerated tendon and ligament healing: Multiple rodent studies have demonstrated faster repair of Achilles tendon, rotator cuff, and anterior cruciate ligament injuries following BPC-157 administration.
• Muscle repair: Studies show accelerated healing of crush injuries, lacerations, and denervated muscle tissue.
• Gut healing: Animal models of inflammatory bowel disease, gastric ulcers, esophageal damage, and fistulas have all shown improvement with BPC-157 treatment.
• Bone healing: Studies suggest enhanced healing of segmental bone defects and fractures, potentially through periosteal cell stimulation.
• Neuroprotection: Preclinical research indicates potential benefits for nerve crush injuries and traumatic brain injury recovery.
• Anti-inflammatory effects: BPC-157 modulates inflammatory cytokine expression, potentially reducing chronic inflammation that impairs healing.
• Gastroprotection: The peptide's origin in gastric juice correlates with protective effects on the stomach lining against NSAID-induced damage.

Animal studies with BPC-157 have generally reported a favorable safety profile, with no documented lethal dose established in rodent models. However, as human clinical trials are limited, a comprehensive human safety profile has not been established.

Anecdotally reported side effects in humans include:

• Nausea or gastrointestinal discomfort, particularly with oral administration
• Dizziness or lightheadedness
• Injection site reactions (with subcutaneous or intramuscular administration)
• Fatigue

Theoretical concerns that have been raised include:

• Potential tumor growth promotion: Because BPC-157 promotes angiogenesis and cell growth, there are theoretical concerns about promoting growth in pre-existing tumors. This has not been observed in animal studies to date, but the risk in humans cannot be ruled out without proper clinical data.
• Drug interactions: Its effects on the NO system and dopaminergic pathways could theoretically interact with medications affecting these systems.

BPC-157 is not approved for human use and should only be considered under proper medical supervision.

Disclaimer: The following information is for educational purposes only. BPC-157 is not FDA-approved for human use. Dosage information is based on extrapolation from animal studies and anecdotal reports from the research community.

Commonly referenced dosage ranges in the literature and research community:

• Injectable (subcutaneous or intramuscular): 200–500 mcg per day, administered once or twice daily near the site of injury — see our subcutaneous injection technique reference
• Oral (capsule form): 500 mcg–1 mg per day; primarily studied for gut-related applications
• Cycle length: Typically 4–8 weeks in animal research protocols

For lyophilized BPC-157 supplied as powder, see our reconstitution walkthrough and the reconstitution calculator for the dosing math. In animal studies, dosages are often expressed as mcg/kg body weight, with common effective doses ranging from 1–10 mcg/kg. Scaling these doses to humans is not straightforward and should not be attempted without medical guidance.

No established human dosing protocol exists. Any use should be under the supervision of a qualified and experienced healthcare provider.

BPC-157 has an unusually extensive preclinical literature for a research peptide, with hundreds of published animal studies. Key findings include:

• Sikiric et al. (1993–present): The University of Zagreb group has produced the bulk of BPC-157 research, demonstrating healing effects in models of tendon injury, IBD, gastric ulcers, and traumatic brain injury.
• Tendon healing studies: Studies in rats consistently show that BPC-157-treated animals achieve superior tensile strength in healed tendons compared to controls.
• Gut studies: BPC-157 has been shown to heal intestinal anastomoses, reduce colitis severity, and accelerate gastric ulcer closure in rodent models.
• Nerve regeneration: Studies have demonstrated improved outcomes in peripheral nerve crush and transection injury models.

Limitations of the current research body include:

• Almost all studies are performed by a single research group, limiting independent replication
• The vast majority of studies are in rodents; primate or human data is extremely limited
• No Phase II or Phase III clinical trials have been completed as of 2026
• Funding and publication bias in a niche research area may affect interpretation of results

BPC-157 remains an active and promising area of research, but definitive clinical evidence supporting its use in humans is not yet available.

Two 2026 peer-reviewed publications have meaningfully advanced the BPC-157 evidence picture, representing the most rigorous synthesis of the research to date.

PMC12313605: First Orthopaedic Sports Medicine Systematic Review

"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review" (2026, PubMed Central) is the first systematic review focused specifically on BPC-157 applications in orthopaedic and sports medicine contexts. Key findings:

• Confirms consistent healing effects across tendon, ligament, and muscle tissue in preclinical models
• Provides structured assessment of human use patterns in athletic and post-surgical contexts — the first systematic review to do so
• Acknowledges that direct human clinical trial evidence remains limited, with most evidence extrapolated from animal studies
• Calls for rigorous human RCTs as the necessary next step before clinical recommendations can be made

PMC12446177: "Regeneration or Risk?" Narrative Review

"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing" (2026, PubMed Central) takes a more critical stance, explicitly acknowledging limitations in the evidence base:

• Human evidence described as "extremely limited — only 3 small, poorly designed studies lacking control groups"
• Highlights publication bias risk from the concentrated source of much BPC-157 research (predominantly from the University of Zagreb group)
• Recommends against clinical use until controlled human trials are completed
• Notes theoretical oncological concerns (angiogenesis promotion) that require investigation in human populations

What This Changes

Taken together, these 2026 reviews represent a more nuanced picture than the largely positive preclinical literature had suggested. The orthopaedic systematic review provides structured confirmation of the animal evidence; the "Regeneration or Risk" review provides a necessary corrective to the risk of overstating what the animal data can tell us about human outcomes.

The evidence classification for BPC-157 has been updated to Level B on this site — reflecting moderate evidence in animal models with limited human data, assessed by the first systematic reviews in this area. Human clinical trial data remains the critical gap.

This data page was last updated April 13, 2026 to reflect these publications.